« Return to News | Drug Sponsors

Pfizer plans to sell Capsugel unit

Tuesday, April 5, 2011 02:57 PM

Pfizer has plans to sell its Capsugel unit to an affiliate of investment firm Kohlberg Kravis Roberts (KKR) for nearly $2.4 billion in cash.  Pfizer’s plans to divest the division to narrow its business focus have been known for a while, according to Pharma Times.

As a result of the Capsugel sale, Pfizer has lowered its sales expectations for the year, given that Capsugel," a world leader in hard capsules and an innovator in drug-delivery systems," pulled in revenues of around $750 million last year.

Henry Kravis and George Roberts, co-founders, chairmen and chief executive of KKR, explained the firm's interest in the deal and highlighted Capsugel's "excellent portfolio and outstanding reputation for providing high-quality, innovative drug-delivery solutions."   They said shared the group's "enthusiasm for its future potential to grow, develop and continue to deliver an unmatched quality of products."

The transaction is expected to close sometime during the third quarter, assuming all customary closing conditions are satisfied.

 

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.